VISTA Antibody: Targeting a Novel Immune Checkpoint

VISTA (V-domain Ig Suppressor of T cell Activation) is an immune checkpoint protein that suppresses the body’s T cell responses, and a growing number of antibody therapies are being designed to block it. First described in 2011 as a structurally distinct member of the immunoglobulin superfamily with resemblance to PD-L1, VISTA has since emerged as a checkpoint with unusual properties: it operates most potently at acidic pH, it is heavily expressed on myeloid immune cells rather than on tumor cells themselves, and it appears to work through pathways that do not overlap neatly with PD-1 or CTLA-4. Those features make it both a promising drug target and a notoriously difficult one to hit safely.

What VISTA Is and How It Was Discovered

VISTA was identified in 2011 as a new inhibitory ligand belonging to the B7 family, the same family that includes the well-known checkpoint ligand PD-L1. Its extracellular domain shares structural homology with PD-L1, but the two molecules are not interchangeable: VISTA has a unique set of binding partners and acts on different immune cell populations under different conditions.¹ Among B7 family members, VISTA is the most evolutionarily conserved, with 76% amino acid identity between mouse and human sequences and the highest sequence identity between mouse and zebrafish genomes of any B7 member. Its cytoplasmic tail is even more conserved, at 91% identity between species.² That level of conservation across hundreds of millions of years of evolution suggests the molecule serves a fundamental purpose in immune regulation.

VISTA’s Normal Job in the Immune System

Before thinking about cancer therapy, it helps to understand what VISTA does when everything is working normally. Its main role appears to be keeping naïve T cells quiet. In mice lacking VISTA, the major population of resting naïve T cells is disrupted, and the animals develop enhanced self-reactivity, meaning their immune cells start attacking their own tissues.³ When researchers specifically deleted VISTA from mouse CD4+ T cells, those mice had fewer naïve T cells and more memory-like T cells, which is exactly what you would expect if a brake on activation had been removed.⁴

A broader knockout study painted a similar picture. Mice completely lacking the VISTA gene gradually accumulated spontaneously activated T cells, produced a range of inflammatory cytokines and chemokines, and were predisposed to autoimmunity under susceptible conditions.⁵ So VISTA functions as a gatekeeper of peripheral tolerance, the process by which your immune system learns not to attack your own body. That is useful context for understanding why blocking VISTA in cancer patients carries autoimmune risks, and also why activating VISTA might someday be useful for treating autoimmune diseases.

How VISTA Suppresses T Cells

When VISTA binds its receptor on T cells, it directly shuts down T cell proliferation and blunts the production of key immune signaling molecules. In human T cell experiments, VISTA suppressed proliferation and blocked the upregulation of the early activation markers CD25 and CD69. It also reduced production of IL-10, TNFα, and IFNγ by both CD4 and CD8 T cells. Under conditions that still allowed some T cell activity, VISTA promoted the conversion of naïve T cells into regulatory T cells (the immune system’s dedicated peacekeepers) by enhancing expression of FoxP3.⁶ In short, VISTA dampens the attack arm of immunity and strengthens the suppressive arm, a double effect that tumors can exploit.

VISTA has multiple binding partners, which adds complexity. The best-characterized interaction at acidic pH is with PSGL-1, an adhesion and co-inhibitory receptor on T cells. Multiple histidine residues on the rim of VISTA’s extracellular domain mediate this binding, and because histidines become protonated at lower pH, the interaction strengthens as conditions become more acidic.⁷ Another reported binding partner is VSIG-8, identified as a VISTA receptor with a measured binding affinity (Kd) in the low micromolar range.⁸ The existence of multiple receptors suggests VISTA can suppress the immune system through more than one pathway, which could be relevant to drug development but also makes predicting therapeutic effects harder.

The Acidic pH Twist and Why It Matters for Tumors

The pH-selective behavior of VISTA is one of the most distinctive things about this checkpoint, and it has reshaped how drug developers think about targeting it. Tumors are famously acidic environments. Rapid cell growth, poor blood supply, and heavy metabolic activity produce lactic acid and other byproducts that drive the pH of tumor tissue down to roughly 6.0–6.5, compared to the normal physiological pH of about 7.4 in the blood. VISTA’s immunosuppressive activity increases precisely in that acidic range, meaning it becomes a more powerful brake on immunity right where tumors need it most.

The connection runs deeper than pH alone. Regions of profound oxygen deprivation (hypoxia) within tumors are associated with the highest VISTA expression. In mouse colon tumor models, VISTA showed the strongest expression in the most hypoxic regions of the tumor, particularly on myeloid-derived suppressor cells (MDSCs), a class of immune cells that tumors recruit to suppress anti-tumor immune responses. Even within the tumor, hypoxic immune cells expressed significantly more VISTA than less hypoxic immune cells, and over 90% of VISTA-expressing myeloid cells co-stained with markers of hypoxia.⁹ The transcription factor HIF-1α, which cells activate in response to low oxygen, can directly upregulate VISTA expression through specific binding sites in the VISTA gene’s promoter.¹⁰

This creates a feedback loop: the hypoxic, acidic core of a tumor upregulates VISTA on the myeloid cells it attracts, and that VISTA becomes maximally active in those same acidic conditions. When VISTA was genetically removed from myeloid cells in mouse tumor models, the population of tumor-associated MDSCs shrank, while anti-tumor dendritic cells and T cell responses expanded.¹¹ The correlation between VISTA expression and the enzyme arginase-1, which supports the immunosuppressive function of MDSCs, has been observed across multiple human cancer types. In human endometrial cancer specifically, co-expression of VISTA and arginase-1 on tumor-associated myeloid cells was associated with worse survival.¹¹

Why VISTA Matters When PD-1 Drugs Fail

PD-1 and PD-L1 inhibitors have transformed cancer treatment, but many patients either never respond or develop resistance over time. VISTA appears to be one of the escape routes tumors use to evade PD-1 therapy. In a study of metastatic melanoma patients treated with anti-PD-1 antibodies, VISTA expression on immune cells within the tumor increased in two-thirds of patients whose disease progressed after initially responding to treatment.¹² The implication is that as PD-1 blockade lifts one set of brakes, the tumor compensates by pressing harder on the VISTA brake.

This compensation makes biological sense because VISTA and PD-1 appear to suppress T cells through non-overlapping pathways. Studies in mice have confirmed that VISTA and PD-1 regulate T cell responses non-redundantly, and combining antibodies against both VISTA and PD-L1 achieved better tumor clearance than blocking either pathway alone.¹³ More recent work has taken this a step further with bispecific antibodies designed to bind both VISTA and PD-L1 simultaneously. In preclinical models of pancreatic, endometrial, and breast cancers, these bispecific antibodies triggered higher secretion of anti-tumor immune molecules like IFN-γ, TNFα, and Granzyme B than either single antibody or a combination of the two separate antibodies.¹⁴

Anti-VISTA Antibodies in Development

Several anti-VISTA antibodies have reached or are approaching clinical trials, but the road has been bumpy. The first to enter the clinic was CI-8993 (originally JNJ-61610588), a fully human IgG1 antibody. That early effort revealed a key problem: because VISTA is abundantly expressed on neutrophils and monocytes circulating in normal blood at physiological pH, a non-pH-selective antibody binds its target in the bloodstream before ever reaching the tumor. This causes rapid drug clearance through a process called target-mediated drug disposition and triggers cytokine release syndrome at doses too low to achieve meaningful levels in tumors.¹⁵ A later phase 1 study of CI-8993 began dose escalation at 0.15 mg/kg, a dose level where some pharmacodynamic activity and target-related clinical findings had been previously observed.¹⁶

The toxicity problem with non-selective antibodies has driven the field toward two strategies. The first is pH-selective antibodies. SNS-101, currently in phase 1 clinical trials, was engineered to bind VISTA preferentially at acidic pH, essentially ignoring the VISTA on cells in normal blood and engaging it only in the acidic tumor microenvironment. Structural analysis at 2.59 Å resolution showed that five of VISTA’s fourteen histidine residues sit at the binding interface with SNS-101, explaining why the interaction is pH-dependent. Single mutations to key histidines (His98, His100, His117) reduced binding affinity by seven- to fourteen-fold.¹⁵

The second strategy is Fc engineering. KVA12.1, another anti-VISTA antibody, targets a unique VISTA epitope and has been engineered with modifications to its IgG1 backbone that increase binding to the neonatal Fc receptor (extending the drug’s half-life in the body) while reducing binding to FcγRIIIa and other activating Fc receptors. The intent is to preserve anti-tumor efficacy while preventing the cytokine release that plagued earlier candidates.¹⁷ As of recent updates, at least three anti-VISTA antibody candidates are in or approaching clinical development.¹⁸

Selecting the Right Patients

Not every tumor has high VISTA expression, and not every patient would be expected to benefit from anti-VISTA therapy. Researchers have begun mapping VISTA expression patterns across solid tumors in the context of other established biomarkers, particularly PD-L1 expression and tumor-infiltrating lymphocyte levels. The goal is to define frameworks that identify which tumor microenvironments are most likely to respond to VISTA blockade, either alone or combined with anti-PD-1 or anti-CTLA-4 therapies.¹⁹ This kind of biomarker-guided patient selection is critical because the PD-1 experience taught the field that broad checkpoint blockade works spectacularly in some patients and does nothing in others, and identifying who will benefit before treatment saves both time and toxicity.

On the imaging front, researchers have developed a radiolabeled version of CI-8993 tagged with zirconium-89, enabling PET imaging of VISTA expression in living subjects. In preclinical models, this tracer showed specific uptake in tumors and spleens expressing human VISTA, and it has been validated for use in a planned human trial.²⁰ If successful in patients, this could provide a non-invasive way to determine whether a patient’s tumor expresses enough VISTA to justify therapy, rather than relying solely on biopsies that only sample a fraction of the tumor.

The Flip Side: Activating VISTA for Autoimmune Disease

In cancer, the goal is to block VISTA so the immune system can attack tumors. In autoimmune diseases, the logic flips: you want to activate VISTA to calm an overactive immune system. This dual-use potential is one of the more interesting aspects of the molecule. In a lupus-prone mouse model, an agonistic VISTA antibody (one that activates rather than blocks the checkpoint) reduced skin disease, autoantibodies, inflammatory cytokines, and the expansion of immune cells that drive lupus.²¹

In a mouse model of inflammatory arthritis driven by neutrophils, an agonistic anti-VISTA antibody reduced disease severity to levels comparable to healthy controls. The effect was tied to a dramatic reduction in neutrophil accumulation in the joints, as measured by myeloperoxidase activity.²² These are still preclinical results, and autoimmune disease in mice does not always predict what happens in humans. But the breadth of conditions where VISTA agonism has shown benefit (lupus, arthritis, and the animal models discussed below) suggests this checkpoint sits at a fairly central node in immune regulation.

VISTA Beyond Cancer and Autoimmunity

Research on VISTA is expanding into unexpected territory. In sepsis, the body’s response to overwhelming infection, VISTA appears to play different roles depending on the stage of illness. During the early hyperinflammatory phase, VISTA signaling may help restrain the cytokine storm and protect organ barriers. During the later immunosuppressive phase, excessive VISTA expression may contribute to the immune paralysis that leaves sepsis patients vulnerable to secondary infections.²³ This stage-dependent behavior complicates any therapeutic approach but also suggests that carefully timed VISTA modulation could help in a condition with few effective immunotherapies.

In the brain, VISTA has shown protective effects after stroke. In a mouse model of cerebral ischemia-reperfusion injury (the damage that occurs when blood flow returns to brain tissue after a stroke), VISTA reduced the volume of dead brain tissue, improved neurological function, and suppressed inflammatory molecules (IL-6, TNFα, IL-1β) while boosting the anti-inflammatory cytokine IL-10. The mechanism involved suppression of microglia, the brain’s resident immune cells, which can cause secondary damage through excessive inflammation after a stroke.²⁴ Whether these findings translate to clinical stroke treatment is far from clear, but they illustrate how broadly VISTA’s immune-suppressive activity can reach when the right conditions are present.

1
PubMed Central. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses
2
PubMed Central. VISTA: Coming of age as a multi‐lineage immune checkpoint
3
PubMed Central. VISTA is a checkpoint regulator for naïve T cell quiescence and peripheral tolerance
4
Trends in Immunology. VISTA Antibody: Targeting a Novel Immune Checkpoint – Section: VISTA on Immune Cells
5
PubMed Central. Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity
6
PubMed Central. VISTA is an immune checkpoint molecule for human T cells
7
PubMed. VISTA is an acidic pH-selective ligand for PSGL-1
8
PubMed. A small molecule inhibitor of VSIG-8 prevents its binding to VISTA
9
PubMed Central. Hypoxia-induced VISTA promotes the suppressive function of myeloid-derived suppressor cells in the tumor microenvironment
10
Trends in Immunology. VISTA Antibody: Targeting a Novel Immune Checkpoint – Section: VISTA Expression and Function as a Receptor or a Ligand
11
PubMed Central. VISTA promotes the metabolism and differentiation of myeloid-derived suppressor cells by STAT3 and polyamine-dependent mechanisms
12
Modern Pathology. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients
13
PubMed Central. Immune-checkpoint proteins VISTA and PD-1 nonredundantly regulate murine T-cell responses
14
PubMed Central. The bispecific antibody targeting VISTA and PD-L1 shows enhanced tumor inhibitory activity in pancreatic, endometrial and breast cancers compared to mono- and combination immune checkpoint blockade
15
Nature Communications. VISTA checkpoint inhibition by pH-selective antibody SNS-101 with optimized safety and pharmacokinetic profiles enhances PD-1 response
16
Journal for ImmunoTherapy of Cancer. Phase 1 study of CI-8993 anti-VISTA antibody in patients with advanced solid tumor malignancies
17
Journal for ImmunoTherapy of Cancer. KVA12.1: an anti-VISTA monoclonal antibody with strong single agent anti-tumor activity and no evidence of cytokine mediated toxicity
18
PubMed Central. Clinical and research updates on the VISTA immune checkpoint: immuno-oncology themes and highlights
19
PubMed Central. VISTA expression and patient selection for immune-based anticancer therapy
20
PubMed Central. Targeting of immune checkpoint regulator V-domain Ig suppressor of T-cell activation (VISTA) with (89)Zr-labelled CI-8993
21
PubMed. PD-1H (VISTA)-mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
22
bioRxiv. The role of VISTA engagement in limiting neutrophil-mediated inflammation
23
PubMed Central. Targeting VISTA for immunomodulation in sepsis: mechanisms and therapeutic potentials
24
PubMed Central. VISTA Alleviates Microglia-Mediated Neuroinflammation After Cerebral Ischemia-Reperfusion Injury via Regulating ACOD1/Itaconic Acid Metabolism